SPRAVATO TREATMENT

 Spravato (generic name: esketamine) is a prescription nasal spray developed by Johnson & Johnson for adults with major depressive disorder (MDD) who have not responded to at least two other antidepressants. It is also approved for use in individuals with MDD who have acute suicidal ideation or behavior, when combined with an oral antidepressant. Unlike traditional antidepressants that primarily target serotonin, norepinephrine, or dopamine, Spravato works by blocking the NMDA receptor, which affects the neurotransmitter glutamate—a key player in mood regulation. 

 Spravato is administered under medical supervision in a certified healthcare setting. Patients are monitored for at least two hours post-administration to ensure safety due to potential side effects such as sedation, dissociation, and increased blood pressure. It is not available for home use. 

 The treatment involves an initial phase with frequent sessions, followed by a maintenance phase with less frequent sessions. Each session includes the administration of the nasal spray, with a required observation period afterward. The specific dosage and frequency are determined by the prescribing healthcare provider based on individual patient needs.